UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Rosiglitazone

In Vitro Substrates

No substrate information.

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Substrate used	Cell System	Reference
SLC22A8	OAT3	Rosiglitazone	0.59	6-carboxyfluorescein	HEK293-OAT3	Zou, 2021
SLC22A6	OAT1	Rosiglitazone	4.2	6-carboxyfluorescein	HEK293-OAT1	Zou, 2021
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	Rosiglitazone	6	Bromsulphthalein	HEK293-OATP1B1	Bachmakov, 2008
SLCO1B3	OATP1B3, OATP8	Rosiglitazone	10.9	Bromsulphthalein	HEK293-OATP1B3	Bachmakov, 2008
SLCO2B1	OATP2B1, OATP-B	Rosiglitazone	5.2	Bromsulphthalein	HEK293-OATP2B1	Bachmakov, 2008
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	Rosiglitazone	43.4	Cerivastatin	HEK-OATP1B1	Tamraz, 2013
ABCC4	MRP4	Rosiglitazone	21	Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC3	MRP3	Rosiglitazone	>133	Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	Rosiglitazone	4.27	Estrone sulfate	HEK-OATP1B1	Tamraz, 2013
SLC22A1	OCT1	Rosiglitazone	6.9	Metformin	MDCK II-OCT1	Bachmakov, 2008
SLC22A1	OCT1	Rosiglitazone	30.4	N-methylpyridinium	MDCK II-OCT1	Bachmakov, 2008
ABCB11	BSEP	Rosiglitazone	2.8	Taurocholate	Sf9 cell membrane vesicles	Morgan, 2013

No drug-drug interaction information.